En vei til effektiv behandling av schizofreni og bipolar mani

 

Publikasjoner


Publikasjonene under kan bestilles fra Bristol-Myers Squibb. Materialet som bestilles, leveres i løpet av 1-2 uker.

 

 

The Antipsychotic Aripiprazole is a Potent


The Antipsychotic Aripiprazole is a Potent, Partial Agonist at the Human 5-HT1A Receptor

 

Jordan et al. European Journal of Pharmacology 2002;441:s137 40

Bestill

Aripiprazole, a Novel Antipsychotic

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

 

Burris et al. Journal of Pharmacology and Experimental Therapeutics 2002;302;1:s381-89

 

Bestill

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597)

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C] Raclopride

 

Yokoi et al. Neuropsychopharmacology 2002;27:s248-59

 

Bestill

Aripiprazole and Haloperidol vs Placebo in Patients With Schizophrenia

Efficacy and Safety of Aripiprazole and Haloperidol vs Placebo in Patients With Schizophrenia and Schizoaffektive Disorder

 

Kane et al. J Clin Psychiatry 2002;63:s763-71

 

Bestill

Aripiprazole and Risperidone vs Placebo in Patients With Schizophrenia

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

 

Potkin et al. Arch Gen Psychiatry. 60(2003):s681-90

 

Bestill

Aripiprazole For the Prevention of Relapse in Stabilized Patients with chronic schizophrenia

Aripiprazole For the Prevention of Relapse in Stabilized Patients with chronic schizophrenia: A placebo-controlled 26-weeks study

 

Pigott et al. J Clin Psychiatry 2003;64:s1048-56

 

Bestill

Efficacy and Safety of Aripiprazol vs Haloperidol

Efficacy and Safety of Aripiprazol vs Haloperidol for Long-Term Maintenance Treatment Following Acute Relaps of Schizophrenia.

 

Kasper et al. Int J Neuropsychopharmacol. 2003;6(4):s325-37.

 

Bestill

A Comparison of Weight Change During Treatment With Olanzapine or Aripiprazol

Comparison of Weight Change During Treatment With Olanzapine or Aripiprazol: Results From a Randomized, Double-Blind Study

 

McQuade et al. J Clin Psychiatry 2004; 65 (suppl 18)

Bestill

Review - Dopamine Parital Agonists

Dopamine Partial Agonists. A New Class of Antipsychotic.

 

Lieberman J. CNS Drugs 2004;18(4):s251-67

 

Bestill

Siste oppdatering: 22-01-2010 Ansvarlig: Robert Österlind
Close

Du forlater nå Bristol-Myers Squibbs nettside. Nettsiden du nå går til, er ikke kontrollert av oss. Vi ber deg være oppmerksom på at Bristol-Myers Squibb ikke er ansvarlig for innholdet på nettsiden du er i ferd med å gå inn på.



Close
Du har gått inn på vår avdeling for leger og helsepersonell. Sidene er ikke ment for pasienter og allmennheten. Er du lege eller helsepersonell?